We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

274 hedge funds and large institutions have $3.85B invested in Intra-Cellular Therapies Inc. in 2022 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 103 increasing their positions, 86 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 35

20% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 86

13% more call options, than puts

Call options by funds: $21.3M | Put options by funds: $18.9M

3% more funds holding

Funds holding: 266 → 274 (+8)

16% less capital invested

Capital invested by funds: $4.57B → $3.85B (-$727M)

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
274
Holders Change
+8
Holders Change %
+3.01%
% of All Funds
4.72%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.12%
New
43
Increased
103
Reduced
86
Closed
35
Calls
$21.3M
Puts
$18.9M
Net Calls
+$2.43M
Net Calls Change
-$6.17M

Top Buyers

1
GKIM
GW&K Investment Management
Massachusetts
+$46.1M
2
Invesco
Invesco
Georgia
+$45.3M
3
Millennium Management
Millennium Management
New York
+$42M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$36.3M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$34.3M

Top Sellers

1
Victory Capital Management
Victory Capital Management
Texas
-$43.9M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$36.5M
3
DCM
Driehaus Capital Management
Illinois
-$29.4M
4
SCM
Suvretta Capital Management
New York
-$25.4M
5
CAM
Cormorant Asset Management
Massachusetts
-$15.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
176
LPL Financial
California
$430K +$13K +249 +3%
PCM
177
Prelude Capital Management
New York
$429K -$99.6K -1,907 -17%
SWM
178
SeaCrest Wealth Management
New York
$423K -$65.2K -1,249 -12%
Canada Pension Plan Investment Board
179
Canada Pension Plan Investment Board
Ontario, Canada
$409K +$460K +8,800 New
ZIM
180
Zacks Investment Management
Illinois
$395K +$68K +1,302 +18%
FRM
181
Fox Run Management
Connecticut
$389K -$18.8K -359 -4%
AI
182
AdvisorShares Investments
Maryland
$376K +$422K +8,076 New
Los Angeles Capital Management
183
Los Angeles Capital Management
California
$375K +$421K +8,054 New
LP
184
LMR Partners
United Kingdom
$368K – – –
PA
185
Profund Advisors
Maryland
$359K -$679 -13 -0.2%
CB
186
Commerce Bank
Missouri
$356K +$124K +2,380 +45%
BHCM
187
Boulder Hill Capital Management
New York
$349K +$392K +7,500 New
LFAS
188
Level Four Advisory Services
Texas
$347K -$364K -6,975 -48%
Ameriprise
189
Ameriprise
Minnesota
$343K -$70.6K -1,352 -16%
FHB
190
First Hawaiian Bank
Hawaii
$335K +$261 +5 +0.1%
AIP
191
Ameritas Investment Partners
Nebraska
$334K +$16.3K +312 +5%
CGH
192
Crossmark Global Holdings
Texas
$325K +$53.6K +1,027 +17%
CP
193
CenterBook Partners
Connecticut
$312K +$350K +6,701 New
CM
194
Caption Management
Oklahoma
$312K +$350K +6,705 New
PNC Financial Services Group
195
PNC Financial Services Group
Pennsylvania
$310K +$40.2K +769 +13%
Mariner
196
Mariner
Kansas
$305K +$342K +6,547 New
VHAM
197
Van Hulzen Asset Management
California
$298K – – –
JG
198
Jefferies Group
New York
$296K +$333K +6,365 New
TRCT
199
Tower Research Capital (TRC)
New York
$291K +$120K +2,297 +58%
Mackenzie Financial
200
Mackenzie Financial
Ontario, Canada
$276K -$2.66M -50,989 -90%
6 7
8
9 10

ITCI Hedge Fund Activity: Q3 2022 in Review

274 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2022, worth a combined $3.85B — down 16% from $4.57B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new ITCI positions and 35 closed out — a net gain of 8 holders — while 103 added to existing stakes and 86 trimmed.

The largest buyer was GW&K Investment Management, adding an estimated $46.1M. The largest seller was Victory Capital Management, cutting an estimated $43.9M.

  • 274 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2022, up from 266 in Q2 2022.
  • Funds reported $3.85B of Intra-Cellular Therapies Inc. stock for Q3 2022, down 16% quarter-over-quarter.
  • 43 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2022 and 35 closed out, a net change of +8 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q3 2022 was GW&K Investment Management, an estimated $46.1M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q3 2022 was Victory Capital Management, an estimated $43.9M sold.

Based on aggregated 13F filings for Q3 2022.